Table 2. Primary outcome analysis.
Group I: Standard antidiabetic medications+ SGLT2 inhibitor; Group II: Standard antidiabetic medications
Data presented as median with the inter-quartile range
Comparison within the group performed by the Wilcoxin test and Friedman test; comparison between groups performed by Mann Whitney U test.
* P < 0.05 compared to Group II; * P < 0.05 compared to baseline; ** P < 0.01 compared to baseline; *** P < 0.001 compared to baseline
| Parameter | Group I, 0 week | Group I, 12 weeks | P value | Group II, 0-week | Group II, 12 weeks | P value |
| MDA (nM/mL) | 13.71 (10.00-27.33) | 9.9 (8.54-17.63) | 0.0476* | 11.68 (10.28-18.97) | 13.18 (11.87-16.99) | 0.7869 |
| NO (µM/L) | 13.83 (10.11-17.75) | 11.00 (10.02-12.32) | 0.0078** | 12.33 (9.99-26.8) | 12.5 (9.49-26.82) | 0.583 |
| GSH (µM/L) | 543.3 (518.3-646.0) | 643.5 (615.0-707.1) | 0.0003*** | 636.3 (560.5-695.4) | 636.2 (542.5-682.1) | 0.3652 |